Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Veridex teams up with US hospital to expand circulating tumour cell testing

This article was originally published in Clinica

Executive Summary

Veridex and the Massachusetts General Hospital are collaborating to further develop the former's circulating tumour cell (CTC) technology. The technology, which captures and counts cancer cells in the blood that have detached from solid tumours, is used to help diagnose cancer and assess patients' prognoses. J&J subsidiary Veridex already markets a CTC test, called CellSearch, which first received 510(k) clearance from the US FDA for monitoring metastatic breast cancer patients in 2004; it is also cleared to monitor metastatic colorectal and prostate cancers (www.clinica.co.uk, 7 December 2007 and 7 March 2008). The new partnership aims to develop a benchtop system for CTC testing, which could be used to guide therapy, as well as for drug discovery applications. As well as counting tumour cells, the next-generation test will also characterise them, Veridex told Clinica. For example, by looking at the cell's genetic information, it could help predict whether a patient will respond to a particular treatment. The company declined to disclose financial details of the deal, and also said it was too soon to say when the new product might be available.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel